Litcius/Paper detail

Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials

Yao Neng Teo, Adriel Z. H. Ting, Yao Hao Teo, Elliot Yeung Chong, Joshua Teik Ann Tan, Nicholas Syn, A. Chia, How Ting Ong, Alex Jia Yang Cheong, Tony Yi‐Wei Li, Kian Keong Poh, Tiong Cheng Yeo, Mark Y. Chan, Raymond Wong, Ping Chai, Ching‐Hui Sia

2022American Journal of Cardiovascular Drugs33 citationsDOI

Topics & Concepts

MedicineEmpagliflozinDapagliflozinCanagliflozinInternal medicineHazard ratioRandomized controlled trialType 2 diabetesMeta-analysisDiabetes mellitusConfidence intervalEndocrinologyDiabetes Treatment and ManagementPancreatic function and diabetesPotassium and Related Disorders
Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials | Litcius